Analyzing Xenetic Biosciences (XBIO) & Its Rivals
Xenetic Biosciences (NASDAQ: XBIO) is one of 283 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Xenetic Biosciences to similar companies based on the strength of its analyst recommendations, earnings, profitability, institutional ownership, risk, valuation and dividends.
This is a summary of recent ratings and price targets for Xenetic Biosciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Xenetic Biosciences Competitors||804||3164||11461||230||2.71|
Volatility & Risk
Xenetic Biosciences has a beta of 8.55, indicating that its stock price is 755% more volatile than the S&P 500. Comparatively, Xenetic Biosciences’ rivals have a beta of 6.03, indicating that their average stock price is 503% more volatile than the S&P 500.
Institutional & Insider Ownership
3.8% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.9% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Xenetic Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Xenetic Biosciences Competitors||-5,336.13%||-476.41%||-40.16%|
Earnings and Valuation
This table compares Xenetic Biosciences and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Xenetic Biosciences||$3.00 million||-$54.20 million||-1.62|
|Xenetic Biosciences Competitors||$286.20 million||$34.74 million||144.16|
Xenetic Biosciences’ rivals have higher revenue and earnings than Xenetic Biosciences. Xenetic Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.